Crescendo are delighted to be celebrating our $70 Million (€57 Million) Series B Financing with investment from new investors, Andera Partners and Quan Capital, and continuing support from existing investors Sofinnova Partners, IP Group, EMBL and Takeda Ventures. The funds will be used to advance the development of our lead programme, CB307 a novel targeted T-cell engager which stimulates local activation of tumour-specific T-cells, and further expand our internal pipeline of Humabody® products.
Cambridge, UK - Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti Ph.D., co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to drug discovery research and science in general.
Synpromics Ltd, the leader in gene control, today announced it has been awarded a £1.9m research and development grant from Scottish Enterprise. The funds will expand Synpromics’ world leading R&D programmes in gene regulation for cell and gene medicines.
IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, and aTen Therapeutics Limited (aTen), a private biopharmaceutical company developing next-generation antibodies for the treatment of cancer, announced today that they have entered into a strategic collaboration. Under the agreement IONTAS will use its proprietary antibody discovery platforms to deliver antibodies against biological targets selected by aTen.
In the latest phase of it development as a new UK biopharmaceutical company Porton Biopharma ltd has officially opened a new state of the art fermentation facility which will manufacture its principle product Erwinase®, used for the treatment of Acute Lymphoblastic Leukaemia.